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GVHD increases the risk of invasive fungal infections (IFIs).
This randomized phase II selection design study was per-
formed to compare the efﬁcacy and safety of voriconazole
(VRCZ: n¼33) and itraconazole (ITCZ: n¼33) in patients with
GVHD.
The study was conducted fromMarch 2009 through October
2011. Adult patients who had undergone allogeneic he-
matopoietic stem cell transplantation were eligible to
participate in the study if they had either grade II to IV acute
GVHD or chronic GVHD requiring corticosteroid treatment (
PSL>¼0.3 mg/kg/day). VRCZ was administered in the form of
tablets at a dose of 200 mg twice daily, and ITCZ was
administered as oral solution at a dose of 2.5 mg/kg twice
daily.
The primary composite endpoint, success of prophylaxis, was
deﬁned as survival without proven/probable IFI for 60 days
and ability to receive study drug for at least 48 of the 60 days
of planned administration.
Age, underlying disease, disease risk, donor type, condi-
tioning intensity and proportion of patients with acute or
chronic GVHD were similar between the two groups. The
proportion of patients who required dose escalation of the
steroid was signiﬁcantly higher in the VRCZ group (VRCZ 32%
vs. ITCZ 9%, P¼.03).
The success rate of prophylaxis was comparable between the
two groups (VRCZ 88% vs. ITCZ 94%; Difference -6.1%, 95% CI
-20 to 7.7%). In the ITCZ group, one patient each developed
probable and possible IFI after 42 and 33 days of prophylaxis,respectively. In the VRCZ group, one patient developed
possible IFI after 59 days of prophylaxis. Therewas no fungal-
related mortality. The causes of prophylaxis failure included
death due to AML, cytopenia, atrial ﬂutter, and catheter-
related infection in the VRCZ group (n¼4), and probable IFI
and withdrawal of consent in the ITCZ group (n¼2).
The incidence of SAE (CTCAE v3 grade 3/4) was not different
between the two groups (VRCZ 27% vs. ITCZ 21%, P¼.77). The
most frequent event was liver dysfunction in both groups
(VRCZ 18% vs. ITCZ 12%, P¼.73), but gastrointestinal events
were seen only in the ITCZ group (VRCZ 0% vs. ITCZ 6%,
P¼.49). A total of 4 patients, exclusively in the ITCZ group,
required intravenous administration of the study drug for
longer than 14 days (20-23 days), and 3 of the 4 patients had
gut acute GVHD. A total of 4 patients received other systemic
anti-mold agents during the study period (VRCZ 9% vs. ITCZ
3%, P¼.61). However, none received these agents for longer
than 14 days (7-10 days) and only one of these patients in the
ITCZ group developed possible IFI.
Both the overall survival rate and the cumulative incidence
rate of non-relapse mortality were similar at 3 years after
randomization between the VRCZ and ITCZ groups (67% vs.
49%, P¼.20 by the log-rank test and 14% vs. 26%, P¼.31 by the
Gray test, respectively).
In conclusion, our study suggested that both VRCZ and ITCZ
were feasible for and effective as an antifungal prophylaxis in
patients with GVHD.103
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Alternative donors (umbilical cord blood (UCB), hap-
loidentical family members, or mismatched unrelated do-
nors (MMUD) allow patients without matched sibling or
unrelated (MUD) donors to proceed to a potentially curative
HCT. Retrospective studies have shown comparable out-
comes among different alternative graft sources, but differ-
ences in infection rates have not been well studied. We
compared incidences of bacterial, viral, and fungal infections
at 1 year post HCT in patients reported to the CIBMTR who
were 16 years with acute leukemia in remission who
received an alternative donor HCT between 2008 and 2011.
Patients were included if they had received HCT in 1st/ 2nd CR
using UCB, 8/8 allele matched MUD or 7/8 antigen/allele
MMUD. Recipients of 467 UCB, 869 MUD and 268 MMUD
grafts were included. UCB recipients were younger and had
better performance status; they were more likely to have
acute lymphoblastic leukemia, not receive antithymocyte
globulin, and be transplanted in CR 2 with reduced intensity
conditioning regimens. The incidence at 1 year of bacterial,
fungal and viral infections in each cohort are shown in Table
1. There were no differences by pairwise comparisons
